Mario R Sampson1, Adam Frymoyer, Benjamin Rattray, C Michael Cotten, P Brian Smith, Edmund Capparelli, Sonia L Bonifacio, Michael Cohen-Wolkowiez. 1. *Duke Clinical Research Institute, Durham; †Department of Pharmacotherapy and Experiment Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC; ‡Department of Pediatrics, Stanford University, Palo Alto, CA; §Department of Pediatrics, Duke University Medical Center, Durham, NC; ¶Schools of Medicine and Pharmacy, University of California San Diego, La Jolla; and ‖Department of Pediatrics, University of California, San Francisco.
Abstract
BACKGROUND: Population pharmacokinetic (popPK) models derived from small pharmacokinetics (PK) studies in neonates are often underpowered to detect clinically important characteristics that drive dosing. External validation of such models is crucial. In this study, the predictive performance of a gentamicin popPK model in neonates receiving hypothermia was evaluated. METHODS: A previously published gentamicin popPK model was developed in neonates with hypoxic ischemic encephalopathy undergoing hypothermia using a retrospective single-institution (University of California-San Francisco) data set. The predictive performance of this model was evaluated in an external retrospective data set from the University of California-San Francisco (validation A) and another from Duke University (validation B). Both institutions used the same hypothermia protocol and collected similar clinical and PK data. Gentamicin dosing and samples were collected per routine care. Predictive performance was evaluated by quantifying the accuracy and precision of model predictions and using simulation-based diagnostics to detect bias in predictions. RESULTS: Forty-one neonates (n = 18 validation A; n = 23 validation B) with median (range) gestational age of 40 weeks (33-42) and birth weight of 3.3 kg (1.9-4.6) and 76 samples (55% troughs, 33% and 28% drawn at 24 and 36 hours after dose, respectively) were analyzed. The model adequately predicted gentamicin concentrations from the same institution (validation A; median average fold error = 1.1 and numerical prediction distribution error P > 0.05) but underpredicted concentrations from the outside institution (validation B; median average fold error = 0.6 and numerical prediction distribution error P < 0.05). CONCLUSIONS: The model demonstrated adequate predictive performance for an external data set in the same institution but not from an outside institution. Larger sample sizes, use of data from multiple institutions, and external evaluation in development of popPK models in neonates may improve generalizability of dosing recommendations arising from single-institution studies.
BACKGROUND: Population pharmacokinetic (popPK) models derived from small pharmacokinetics (PK) studies in neonates are often underpowered to detect clinically important characteristics that drive dosing. External validation of such models is crucial. In this study, the predictive performance of a gentamicin popPK model in neonates receiving hypothermia was evaluated. METHODS: A previously published gentamicin popPK model was developed in neonates with hypoxic ischemic encephalopathy undergoing hypothermia using a retrospective single-institution (University of California-San Francisco) data set. The predictive performance of this model was evaluated in an external retrospective data set from the University of California-San Francisco (validation A) and another from Duke University (validation B). Both institutions used the same hypothermia protocol and collected similar clinical and PK data. Gentamicin dosing and samples were collected per routine care. Predictive performance was evaluated by quantifying the accuracy and precision of model predictions and using simulation-based diagnostics to detect bias in predictions. RESULTS: Forty-one neonates (n = 18 validation A; n = 23 validation B) with median (range) gestational age of 40 weeks (33-42) and birth weight of 3.3 kg (1.9-4.6) and 76 samples (55% troughs, 33% and 28% drawn at 24 and 36 hours after dose, respectively) were analyzed. The model adequately predicted gentamicin concentrations from the same institution (validation A; median average fold error = 1.1 and numerical prediction distribution error P > 0.05) but underpredicted concentrations from the outside institution (validation B; median average fold error = 0.6 and numerical prediction distribution error P < 0.05). CONCLUSIONS: The model demonstrated adequate predictive performance for an external data set in the same institution but not from an outside institution. Larger sample sizes, use of data from multiple institutions, and external evaluation in development of popPK models in neonates may improve generalizability of dosing recommendations arising from single-institution studies.
Authors: L S Miall; M J Henderson; A J Turner; K G Brownlee; J T Brocklebank; S J Newell; V L Allgar Journal: Pediatrics Date: 1999-12 Impact factor: 7.124
Authors: Wei Zhao; Florentia Kaguelidou; Valérie Biran; Daolun Zhang; Karel Allegaert; Edmund V Capparelli; Nick Holford; Toshimi Kimura; Yoke-Lin Lo; José-Esteban Peris; Alison Thomson; John N van den Anker; May Fakhoury; Evelyne Jacqz-Aigrain Journal: Br J Clin Pharmacol Date: 2013-04 Impact factor: 4.335
Authors: Elke H J Krekels; Joost DeJongh; Richard A van Lingen; Caroline D van der Marel; Imti Choonara; Anne M Lynn; Meindert Danhof; Dick Tibboel; Catherijne A J Knibbe Journal: Clin Pharmacokinet Date: 2011-01 Impact factor: 6.447
Authors: Seetha Shankaran; Abbot R Laptook; Richard A Ehrenkranz; Jon E Tyson; Scott A McDonald; Edward F Donovan; Avroy A Fanaroff; W Kenneth Poole; Linda L Wright; Rosemary D Higgins; Neil N Finer; Waldemar A Carlo; Shahnaz Duara; William Oh; C Michael Cotten; David K Stevenson; Barbara J Stoll; James A Lemons; Ronnie Guillet; Alan H Jobe Journal: N Engl J Med Date: 2005-10-13 Impact factor: 91.245
Authors: Adam Frymoyer; Lina Meng; Sonia L Bonifacio; Davide Verotta; B Joseph Guglielmo Journal: Pharmacotherapy Date: 2013-04-01 Impact factor: 4.705
Authors: A Frymoyer; S Lee; S L Bonifacio; L Meng; S S Lucas; B J Guglielmo; Y Sun; D Verotta Journal: J Perinatol Date: 2013-05-23 Impact factor: 2.521